Rockefeller Capital Management L.P. Acquires 16,116 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Rockefeller Capital Management L.P. lifted its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 3.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 453,708 shares of the company’s stock after acquiring an additional 16,116 shares during the period. Rockefeller Capital Management L.P. owned approximately 0.98% of Omnicell worth $19,777,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in OMCL. Walleye Capital LLC raised its position in Omnicell by 44.0% in the 3rd quarter. Walleye Capital LLC now owns 18,214 shares of the company’s stock valued at $794,000 after buying an additional 5,569 shares during the last quarter. Martingale Asset Management L P purchased a new stake in shares of Omnicell in the third quarter valued at about $507,000. PEAK6 Investments LLC purchased a new position in Omnicell during the third quarter worth about $448,000. Millrace Asset Group Inc. bought a new stake in Omnicell in the 3rd quarter worth about $1,223,000. Finally, The Manufacturers Life Insurance Company increased its stake in Omnicell by 7.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 25,272 shares of the company’s stock valued at $1,102,000 after buying an additional 1,813 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Stock Down 3.9 %

OMCL opened at $46.59 on Monday. The firm has a 50-day moving average price of $44.55 and a 200-day moving average price of $38.05. Omnicell, Inc. has a twelve month low of $25.12 and a twelve month high of $55.74. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of -119.46, a PEG ratio of 35.40 and a beta of 0.81.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. JPMorgan Chase & Co. boosted their target price on Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research note on Thursday, November 21st. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a research note on Wednesday, November 27th. Wells Fargo & Company lifted their target price on Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research note on Monday, October 14th. Bank of America reissued a “neutral” rating and issued a $57.00 price target (up from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Finally, Craig Hallum lifted their price objective on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, Omnicell has an average rating of “Hold” and an average target price of $52.00.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.